Total Payments
$146,048
2024 Payments
$2,876
Companies
6
Transactions
27
Medicare Patients
891
Medicare Billing
$149,941
Payment Breakdown by Category
Research$125,132 (85.7%)
Consulting$13,632 (9.3%)
Other$4,380 (3.0%)
Travel$2,477 (1.7%)
Food & Beverage$426.41 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $125,132 | 2 | 85.7% |
| Consulting Fee | $13,632 | 4 | 9.3% |
| Travel and Lodging | $2,477 | 11 | 1.7% |
| Honoraria | $2,400 | 1 | 1.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,980 | 1 | 1.4% |
| Food and Beverage | $426.41 | 8 | 0.3% |
Payments by Type
Research
$125,132
2 transactions
General
$20,915
25 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $125,132 | 2 | $0 (2023) |
| Celgene Corporation | $8,042 | 6 | $0 (2019) |
| EISAI INC. | $5,790 | 12 | $0 (2019) |
| Exelixis Inc. | $2,876 | 4 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $2,227 | 2 | $0 (2022) |
| Progenics Pharmaceuticals, Inc. | $1,980 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,876 | 4 | Exelixis Inc. ($2,876) |
| 2023 | $125,132 | 2 | Eli Lilly and Company ($125,132) |
| 2022 | $4,207 | 3 | Ipsen Biopharmaceuticals, Inc ($2,227) |
| 2019 | $13,832 | 18 | Celgene Corporation ($8,042) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $295.13 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Travel and Lodging | In-kind items and services | $70.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 01/25/2024 | Exelixis Inc. | CABOMETYX (Drug) | Honoraria | Cash or cash equivalent | $2,400.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 01/17/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $110.54 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 05/01/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $104,276.95 | Research |
| 03/06/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $20,855.39 | Research |
| 12/01/2022 | Ipsen Biopharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $2,175.00 | General |
| 10/29/2022 | Ipsen Biopharmaceuticals, Inc | — | Consulting Fee | Cash or cash equivalent | $52.25 | General |
| 02/23/2022 | Progenics Pharmaceuticals, Inc. | AZEDRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,980.00 | General |
| Category: RADIOPHARMACEUTICAL | ||||||
| 11/22/2019 | EISAI INC. | Lenvima (Drug) | Consulting Fee | Cash or cash equivalent | $4,625.00 | General |
| Category: Oncology | ||||||
| 11/22/2019 | EISAI INC. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $333.54 | General |
| Category: Oncology | ||||||
| 11/22/2019 | EISAI INC. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $225.94 | General |
| Category: Oncology | ||||||
| 11/22/2019 | EISAI INC. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $195.00 | General |
| Category: Oncology | ||||||
| 11/22/2019 | EISAI INC. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $110.46 | General |
| Category: Oncology | ||||||
| 11/22/2019 | EISAI INC. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $93.31 | General |
| Category: Oncology | ||||||
| 11/22/2019 | EISAI INC. | Lenvima (Drug) | Travel and Lodging | Cash or cash equivalent | $57.00 | General |
| Category: Oncology | ||||||
| 11/22/2019 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $50.00 | General |
| Category: Oncology | ||||||
| 11/22/2019 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $48.54 | General |
| Category: Oncology | ||||||
| 11/22/2019 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $25.42 | General |
| Category: Oncology | ||||||
| 11/22/2019 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $12.93 | General |
| Category: Oncology | ||||||
| 11/22/2019 | EISAI INC. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $12.93 | General |
| Category: Oncology | ||||||
| 05/17/2019 | Celgene Corporation | Abraxane (Drug) | Consulting Fee | Cash or cash equivalent | $6,780.00 | General |
| Category: Oncology | ||||||
| 05/17/2019 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | Cash or cash equivalent | $134.30 | General |
| Category: Oncology | ||||||
| 05/17/2019 | Celgene Corporation | Abraxane (Drug) | Travel and Lodging | Cash or cash equivalent | $70.00 | General |
| Category: Oncology | ||||||
| 05/17/2019 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | Cash or cash equivalent | $31.75 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 257 | 420 | $231,522 | $41,961 |
| 2022 | 3 | 188 | 332 | $164,941 | $31,334 |
| 2021 | 6 | 228 | 438 | $180,527 | $42,103 |
| 2020 | 6 | 218 | 437 | $142,519 | $34,542 |
Total Patients
891
Total Services
1,627
Medicare Billing
$149,941
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 58 | 98 | $71,948 | $11,888 | 16.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 46 | 67 | $49,558 | $8,155 | 16.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 51 | 91 | $36,873 | $7,270 | 19.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 31 | 60 | $24,205 | $4,851 | 20.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 27 | 60 | $16,680 | $4,052 | 24.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 17 | 17 | $15,019 | $2,563 | 17.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $14,148 | $2,415 | 17.1% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 11 | 11 | $3,091 | $765.82 | 24.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 67 | 129 | $51,643 | $10,289 | 19.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 50 | 112 | $44,876 | $9,076 | 20.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 23 | 35 | $24,892 | $4,256 | 17.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 24 | 32 | $22,794 | $3,910 | 17.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $11,243 | $2,053 | 18.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 11 | 11 | $9,493 | $1,750 | 18.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 74 | 202 | $68,278 | $16,607 | 24.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 29 | 72 | $24,568 | $6,307 | 25.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 27 | 37 | $22,615 | $4,758 | 21.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 19 | 45 | $17,955 | $4,034 | 22.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 23 | 23 | $17,254 | $3,725 | 21.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $11,732 | $2,591 | 22.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 21 | 21 | $12,371 | $2,416 | 19.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2021 | 19 | 22 | $5,754 | $1,663 | 28.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 95 | 246 | $66,826 | $16,476 | 24.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 22 | 74 | $27,862 | $6,785 | 24.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 29 | 29 | $17,112 | $4,187 | 24.5% |
About Kimberly Perez
Kimberly Perez is a Hematology healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/19/2007. The National Provider Identifier (NPI) number assigned to this provider is 1659598191.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Kimberly Perez has received a total of $146,048 in payments from pharmaceutical and medical device companies, with $2,876 received in 2024. These payments were reported across 27 transactions from 6 companies. The most common payment nature is "" ($125,132).
As a Medicare-enrolled provider, Perez has provided services to 891 Medicare beneficiaries, totaling 1,627 services with total Medicare billing of $149,941. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Location Providence, RI
- Active Since 04/19/2007
- Last Updated 07/08/2007
- Taxonomy Code 207RH0000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1659598191
Products in Payments
- Abraxane (Drug) $7,312
- Lenvima (Drug) $5,790
- CABOMETYX (Drug) $2,876
- AZEDRA (Drug) $1,980
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology Doctors in Providence
William Sikov, Md, MD
Hematology — Payments: $214,835
Hematology $214,835
Wafik El Deiry, Md, MD
Hematology — Payments: $3,821
Hematology $3,821
Dr. Jeremy Warner, Md, MD
Hematology — Payments: $2,900
Hematology $2,900
Angela Taber, Md, MD
Hematology — Payments: $1,379
Hematology $1,379
Sherise Rogers, M.d, M.D
Hematology — Payments: $375.85
Hematology $375.85
Mirela Stancu, M.d, M.D
Hematology — Payments: $226.97
Hematology $226.97